Payment overview · 2025
General Payments
$499.39
25 reported records · 8 companies
Healthcare provider profile · identity verified
Autumn Clark, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SPRINGFIELD, MO · NPI 1912911090
Verified facts
What the public records show
CMS Open Payments records show Autumn Clark, DO received $499.39 in general payments during 2025 across 25 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Ingrezza, Lybalvi, Rexulti.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Lybalvi by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Caplyta by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $211.19 | 42.3% | 16 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $101.49 | 20.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $67.98 | 13.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.86 | 8.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.39 | 4.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.92 | 4.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $19.39 | 3.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.17 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $397.90 | 24 |
| Education | $101.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $211.19 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $67.98 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 400 | 53 |
| Lamotrigine | Lamotrigine | 265 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 260 | 36 |
| Trazodone Hcl | Trazodone Hcl | 252 | 46 |
| Diazepam | Diazepam | 233 | 26 |
| Bupropion Xl | Bupropion Hcl | 227 | 29 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 225 | 32 |
| Gabapentin | Gabapentin | 223 | 33 |
| Lorazepam | Lorazepam | 211 | 27 |
| Olanzapine | Olanzapine | 165 | 23 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 163 | 24 |
| Methylphenidate Hcl | Methylphenidate Hcl | 150 | 22 |
| Buspirone Hcl | Buspirone Hcl | 148 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 137 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 20 |
| Mirtazapine | Mirtazapine | 130 | 28 |
| Aripiprazole | Aripiprazole | 129 | 22 |
| Lurasidone Hcl | Lurasidone Hcl | 128 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 127 | 21 |
| Trintellix | Vortioxetine Hydrobromide | 127 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 20 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 117 | 18 |
| Sertraline Hcl | Sertraline Hcl | 102 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 101 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 16 |
| Vraylar | Cariprazine Hcl | 94 | 14 |
| Eszopiclone | Eszopiclone | 83 | 12 |
| Belsomra | Suvorexant | 81 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 81 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 81 | 13 |
| Alprazolam | Alprazolam | 76 | 13 |
| Ingrezza | Valbenazine Tosylate | 74 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 73 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 72 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 72 | suppressed |
| Topiramate | Topiramate | 70 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 66 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 66 | suppressed |
| Paliperidone Er | Paliperidone | 64 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 62 | 11 |
| Doxepin Hcl | Doxepin Hcl | 60 | suppressed |
| Haloperidol | Haloperidol | 56 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 55 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 53 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 49 | 13 |
| Oxcarbazepine | Oxcarbazepine | 48 | suppressed |
| Amantadine | Amantadine Hcl | 46 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 44 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 43 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Rexulti | Brexpiprazole | 42 | suppressed |
| Caplyta | Lumateperone Tosylate | 40 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Olanzapine Odt | Olanzapine | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 28 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 23 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 22 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 21 | suppressed |
| Zaleplon | Zaleplon | 21 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Abilify Maintena | Aripiprazole | 19 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 13 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $499.39 · 25 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ARISTADA, Auvelity, CAPLYTA, COBENFY, INGREZZA, LYBALVI, Qelbree, REXULTI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error